Drug
Myl 1701p
Myl 1701p: highest development phase Phase 3, developed by Viatris. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Viatris
Trials
| Drug | Phase | Indication |
|---|---|---|
| MYL-1701P, a proposed biosimilar to Eylea NCT04674800 | Phase 3 | Diabetic Macular Edema |
Latest
No recent events.
Follow Myl 1701p on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.